Factor | Age | D-fascia preservation | Puboprostatic ligament sparing | Selective/no ligation of DVC | pT2 cancer percent | Selection Score of Oncologic Safety | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β ± SE | P-value | β ± SE | P-value | β ± SE | P-value | β ± SE | P-value | β ± SE | P-value | β ± SE | P-value | |
Total PSM rate in all-stage | 0.013 ± 0.006 | 0.044 | −0.032 ± 0.037 | 0.385 | −0.022 ± 0.039 | 0.561 | 0.021 ± 0.045 | 0.643 | −0.004 ± 0.002 | 0.012 | −0.013 ± 0.005 | 0.012 |
PSM rate in pT2 cancer | 0.005 ± 0.005 | 0.303 | 0.011 ± 0.032 | 0.727 | −0.050 ± 0.032 | 0.120 | −0.044 ± 0.033 | 0.183 | – | – | – | – |
PSM rate in pT3 cancer | 0.041 ± 0.018 | 0.025 | −0.001 ± 0.097 | 0.990 | 0.111 ± 0.075 | 0.139 | −0.111 ± 0.074 | 0.133 | – | – | – | – |